Advertisement

Striatal Dopamine-γ-Aminobutyric Acid-Acetylcholine Interaction in Organophosphate-Induced Neurotoxicity

  • I. K. Ho
  • S. P. Sivam
  • John C. R. Fernando
  • D. K. Lim
  • B. Hoskins
Part of the Advances in Behavioral Biology book series (ABBI, volume 30)

Abstract

The extreme toxicity of organophosphate cholinesterase inhibitors (OP-ChE-Is) is due to their irreversible inactivation of acetylcholinesterase (AChE), resulting in cholinergic hyperactivity (19). It has been suggested that various cholinergically-mediated behaviors would be disrupted only if the AChE activity in brain fell below some critical level, i.e., 40% of normal (16, 35). However, some of the behavioral changes induced by OP-ChE-Is do not entirely correlate with the degree of AChE inhibition (4, 11, 18, 21, 42). Therefore, the question of whether all of the toxic symptoms are due to the derangement of cholinergic function or if other neurochemical changes might be, in part, responsible is unclear.

Keywords

AChE Activity AChE Inhibition Cholinergic Function DOPAC Level Aminooxyacetic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Askew,W.E. and Ho,B.T. (1975): Canad.J. Biochem. 53: 634–635.Google Scholar
  2. 2.
    Bellet, E.M., and Casida, J.E. (1973): Science 182: 1135–1136.CrossRefGoogle Scholar
  3. 3.
    Bowery, N.G., Collins, F.F. and Hill, R.G. (1976): Nature 261: 601–603.CrossRefGoogle Scholar
  4. 4.
    Burchfield, J.L., Duffy, F.H and Sim, V.M. (1976): Toxicol. Appl. Pharmacol. 35: 365–379.Google Scholar
  5. 5.
    Costa, E., Guidotti, A. and Mao, C.C. (1976): In: GABA in Nervous System Function (eds) E. Roberts, T.N. Chase and D.B. Tower, Raven Press, New York, pp. 413–42 6.Google Scholar
  6. 6.
    Costa, L.G., Schwab, B.W. and Murphy, S.D. (1982): Toxicol. 25: 79–97.CrossRefGoogle Scholar
  7. 7.
    Dasheiff, R.M., Einberg, E. and Grenell, R.G. (1977): Exptl. Neurol. 57: 549–560.CrossRefGoogle Scholar
  8. 8.
    Davis, K.L., Yesavage,J.A. and Berger, P.A. (1978): J. Nervous Mental Disease 166: 222–225.CrossRefGoogle Scholar
  9. 9.
    Dawson, R.M. and Jarrott, B. (1981): Biochem. Pharmacol. 30: 2365–2368.CrossRefGoogle Scholar
  10. 10.
    Enna, S.J. (1981): Biochem. Pharmacol. 30: 907–913.CrossRefGoogle Scholar
  11. 11.
    Faff, J., Borkoruska, E., Bak, W. (1976): Arch. Toxicol. 36: 139–146.Google Scholar
  12. 12.
    Fernando, J.C.R., Hoskins, B. and Ho, I.K. (1984): Pharmacology, Biochemistry, Behavior 20: 951–957.Google Scholar
  13. 13.
    Freed, V.H., Matin, M.A., Fang, S.C. and Kar, P.P. (1976): Eur. J. Pharmacol. 35: 229–232.CrossRefGoogle Scholar
  14. 14.
    Glisson, S.N., Karczmar, A.G. and Barnes, L. (1972): Neuropharmacology 11: 465–477.CrossRefGoogle Scholar
  15. 15.
    Glisson, S.N.,Karczmar, A.G., Barnes, L. (1974): Neuropharmacology 13:623–631.Google Scholar
  16. 16.
    Glow, P.H. and Rose, S. (1965): Nature 206: 475–477.CrossRefGoogle Scholar
  17. 17.
    Goldberg, A.L. and Singer, J.J. (1969): Proc. Nat. Acad. Sci, USA 64: 134–141.Google Scholar
  18. 18.
    Green, D.M., Muir, A.W., Stratton, J.A. and Inch, T.D. (1977) J. Pharm. Pharmacol. 29: 62–64.Google Scholar
  19. 19.
    Holmstedt, B. (1959): Pharmacol. Rev. 11: 567–688.Google Scholar
  20. 20.
    Hornykiewicz, 0. (1975): Biochem. Pharmacol. 24: l061–1065.CrossRefGoogle Scholar
  21. 21.
    Kozar, M.D., Overstreet, D.H., Chippendale, T.C. and Russell R.W. (1976): Neuropharmacol. 15: 291–298.CrossRefGoogle Scholar
  22. 22.
    Lim, D.K. Hoskins, B. and Ho, I.K, (1983): Res. Comm. Chem. Pathol. Pharmacol. 39: 399–418.Google Scholar
  23. 23.
    Lipp, J.A. (1973): Arch. Int. Pharmacodyn. 202: 244–251.Google Scholar
  24. 24.
    Lundy, P.M. and Magor, G. (1978): J. Pharm. Pharmacol. 30: 251–252.Google Scholar
  25. 25.
    Lundy, P.M. Magor, G. and Shaw, R.K. (1978): Arch. Int. Pharmacodyn. 234: 64–73.Google Scholar
  26. 26.
    Lundy, P.M. and Shaw, R.K. (1983): Neuropharmacology 22: 55–63.CrossRefGoogle Scholar
  27. 27.
    Mao, C.C., Guidotti, A. and Costa, E. (1974): Brain Res. 75: 510–514.CrossRefGoogle Scholar
  28. 28.
    Matin, M.A. and Kar, P.P. (1973): Eur. J. Pharmacol. 21: 217–221.CrossRefGoogle Scholar
  29. 29.
    Meeter, E. and Wolthuis, 0.L. (1968): Eur. J. Pharmacol. 2: 377–386.CrossRefGoogle Scholar
  30. 30.
    Quastel, J.H. (1962): In: Neurochemistry (K.A.C. Elliot, I.H. Page and J.H. Quastel, eds.), Charles C. Thomas, Springfield, pp. 431–451.Google Scholar
  31. 31.
    Roberts, E., Chase, T.N. and Tower, D.B. (1976): Nervous System Function Raven Press, New York.Google Scholar
  32. 32.
    Rump, S., Grudzinska, E. and Edelwejn, Z. (1973): Neuropharmacology 12: 813–817.CrossRefGoogle Scholar
  33. 33.
    Russell, R.W., Overstreet, D.H. Cotman, C.W., Carson, V.G., Churchill, L., Dalglish, F.W. and Vasquez, B.J. (1975): J. Pharmacol. Exp. There. 192: 73–85.Google Scholar
  34. 34.
    Russell, R.W., Vasquez, B.J., Overstreet, D.H. and Dalglish, F.W. (1971): Psychopharmacologia 20: 32–41.CrossRefGoogle Scholar
  35. 35.
    Russell, R.W., Watson, R.H.J. and Trankenhaeuser, M. (1961): Scad. J. Physiol. 2: 21–29.Google Scholar
  36. 36.
    Seeman, P. (1981): Pharmacol. Rev. 32: 229–313.Google Scholar
  37. 37.
    Sevaljevic, L., Krtolica, K. Poznanovic, G., Boskovic, B. and Maksimovic, M. (1981): Biochem. Pharmacol. 30: 2725–2727.CrossRefGoogle Scholar
  38. 38.
    Sivam, S.P., Hoskins, B. and Ho, I.K. (1984): Fundamen. Appl. Toxicol. 4: 531–538.Google Scholar
  39. 39.
    Sivam, S.P., Nabeshima, T., Lim, D.K., Hoskins, B. and Ho, I.K., (1983): Res. Comm. Chem. Pathol. Pharmacol. 42: 51–60.Google Scholar
  40. 40.
    Sivam, S.P., Norris, J.C., Lim, D.K. Hoskins, B. and Ho, I.K. (1983): J. Neurochem. 40: 1414–1422.CrossRefGoogle Scholar
  41. 41.
    Stitcher, D.L., Harris, L.W., Moore, R.D. and Heyl, W.C. (1977): Toxicol. Appl. Pharmacol. 41: 79–90.Google Scholar
  42. 42.
    Wecker, L., Mobley, P.L. and Dettbarn, W-D. (1977): Biochem. Pharmacol. 26: 633–637.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • I. K. Ho
    • 1
  • S. P. Sivam
    • 1
  • John C. R. Fernando
    • 1
  • D. K. Lim
    • 1
  • B. Hoskins
    • 1
  1. 1.Department of Pharmacology and ToxicologyUniversity of Mississippi Medical CenterJacksonUSA

Personalised recommendations